Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet

Li Xu, Danping Huang, Qiaolin Hu, Jing Wu, Yizhen Wang and Jie Feng*

Key Laboratory of Molecular Animal Nutrition, Ministry of Education, College of Animal Sciences, Zhejiang University, Hangzhou 310029, People’s Republic of China

(Submitted 15 October 2014 – Final revision received 9 February 2015 – Accepted 11 March 2015 – First published online 29 April 2015)

Abstract

To assess the effects of betaine on hepatic lipid accumulation and investigate the underlying mechanism, thirty-two male Sprague–Dawley rats weighing 100 (SD 2.50) g were divided into four groups, and started on one of four treatments: basal diet, basal diet with betaine administration, high-fat diet and high-fat diet with betaine administration. The results showed that no significant difference of body weight was found among experimental groups. Compared with high-fat diet-fed rats, a betaine supplementation decreased (P<0.05) hepatic TAG accumulation induced by high-fat diet, which was also supported by hepatic histology results. Additionally, hepatic betaine–homocysteine methyltransferase activity as well as its mRNA abundance and lecithin level were found increased (P<0.05) by betaine supplementation in both basal diet-fed rats and high-fat diet-fed rats. Betaine administration in high-fat diet-fed rats exhibited a higher (P<0.05) activity of hepatic carnitine palmitoyltransferase 1 (CPT1) compared with high-fat diet-fed rats. High-fat diet inhibited (P<0.05) the gene expression of hepatic PPARa and CPT1. However, betaine administration in high-fat diet-fed rats elevated (P<0.05) the gene expression of PPARa and CPT1. Moreover, concentration, gene and protein expressions of hepatic fibroblast growth factor 21 (FGF21) were increased (P<0.05) in response to betaine administration in high-fat diet-fed group; meanwhile the gene expression of hepatic AMP-activated protein kinase was increased (P<0.05) as well. The results suggest that betaine administration enhanced hepatic lipid export and fatty acid oxidation in high-fat diet-fed rats, thus effectively alleviating fat accumulation in the liver.

Key words: Betaine: Liver: Lipid accumulation: High-fat diet: Rats

Betaine (N,N,N-trimethylglycine) that serves as an effective methyl donor and an osmolyte is commonly used in animals and human beings for the purpose of sparing dietary methionine, and helping to treat homocysteinaemia separately. In vivo, betaine plays a key role in sulphur-amino acid metabolism, and is metabolised to dimethylglycine and sarcosine. Numerous studies indicate that betaine has important nutritional and physiological functions, such as growth promotion, anti-stress effect, reproductive performance improvement, antioxidant preventive effect as well as osmotic protection. Furthermore, studies on swine and poultry have suggested that betaine supplementation can decrease overall fat deposition, and improve carcass characteristics by stimulating lipolysis. Clinical studies have shown that betaine might serve as a safe and promising therapeutic agent for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in human beings. Lipid accumulation results from an imbalance among the synthesis, oxidation and transportation of fatty acids, and plays a key role in disease initiation, which can be seen in many chronic liver diseases. Therefore, the beneficial effects of betaine in preventing hepatic fat accumulation have received much attention in recent years. In rats and human subjects, high-fat diet, ethanol as well as high sucrose induced hepatic lipid accumulation and liver injury, and these changes could be reversed by the administration of betaine. Previous studies indicated that betaine triggers hepatoprotective effect mostly through alleviating impairment of sulphur-amino acid metabolism and oxidative stress.

However, the effects of betaine on hepatic lipid accumulation and molecular mechanisms behind these alterations were not fully clarified. Therefore, the present study focused on the effects of betaine on hepatic lipid accumulation, and investigated the regulation interrelationship between betaine and related key factors involved in protective effects against abnormal lipid accumulation in Sprague–Dawley rats.

Materials and methods

Animal experimental procedure

The present study was approved by the Institutional Animal Care and Use Committee of Zhejiang University.

Abbreviation: CPT1, carnitine palmitoyltransferase 1.

*Corresponding author: Professor J. Feng, email fengj@zju.edu.cn
(Hangzhou, China). The experiment was conducted in the Laboratory Animal Center of Zhejiang University, and all necessary precautions were taken to mitigate pain. Sprague–Dawley rats used for the investigation were purchased from Medical Animal Laboratory Center of Zhejiang Chinese Medical University (Hangzhou, China). Thirty-two 3-week-old male Sprague–Dawley rats (initial weight: 100 (sd 2·50) g) were randomly divided into four different groups: basal diet (T1), basal diet with betaine administration (T2), high-fat diet (T3) and high-fat diet with betaine administration (T4). T1 and T2 were given basal diet (Table 1), while T3 and T4 were given high-fat diet (Table 1). Meanwhile, T2 and T4 were administrated intragastrically with 1 ml of betaine (98% of purity; Sigma-Aldrich) at a concentration of 400 mg/kg at 17.00 hours per d, while T1 and T3 groups were given 1 ml of 0·9% saline by oral administration. The energy compositions of basal diet were 13·8% derived from fat, 25·7% from protein and 60·5% from carbohydrates (Table 1). In high-fat diet, 40·0% of its energy derived from fat, 20·0% from protein and 60·5% from carbohydrates (Table 1). The diets were formulated according to AIN-93G (American Institute of Nutrition recommendation for laboratory rodents) (24). The basal and high-fat diets were prepared specifically for our study by Slac Experimental Animal LLC (Shanghai, China). A schedule of 12 h light and 12 h darkness was used for the Sprague–Dawley rats. All rats were individually housed in a stainless steel cage and had free access to chow diet and water throughout the entire feeding period. Body weights of rats were recorded weekly. The experiments lasted for 28 d.

**Table 1.** Nutrition formulation of diet*

<table>
<thead>
<tr>
<th>Ingredient (g/kg)</th>
<th>Basal diet</th>
<th>High-fat diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maize starch</td>
<td>504·48</td>
<td>233·24</td>
</tr>
<tr>
<td>Casein</td>
<td>230·00</td>
<td>227·58</td>
</tr>
<tr>
<td>Sucrose</td>
<td>100·00</td>
<td>194·60</td>
</tr>
<tr>
<td>Soyabean oil</td>
<td>60·00</td>
<td>32·76</td>
</tr>
<tr>
<td>Lard oil</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fibre</td>
<td>50·00</td>
<td>27·30</td>
</tr>
<tr>
<td>Mineral mix†</td>
<td>35·00</td>
<td>35·00</td>
</tr>
<tr>
<td>Vitamin mix†</td>
<td>10·00</td>
<td>10·00</td>
</tr>
<tr>
<td>L-Cys</td>
<td>3·00</td>
<td>3·00</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2·50</td>
<td>2·50</td>
</tr>
<tr>
<td>Antioxidant</td>
<td>0·02</td>
<td>0·02</td>
</tr>
<tr>
<td>Nutrient level (g/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>520·00</td>
<td>446·00</td>
</tr>
<tr>
<td>Crude protein</td>
<td>221·00</td>
<td>223·00</td>
</tr>
<tr>
<td>Crude lipid</td>
<td>52·80</td>
<td>196·00</td>
</tr>
</tbody>
</table>

Fatty acid composition (%)

| C14 : 0       | 0·10  | 0·90     |
| C16 : 0       | 9·90  | 20·20    |
| C16 : 1       | 0·20  | 3·80     |
| C18 : 0       | 3·70  | 9·90     |
| C18 : 1n-9    | 21·40 | 36·80    |
| C18 : 2n-6    | 54·10 | 24·60    |
| C18 : 3n-3    | 8·80  | 3·10     |
| C20 : 1n-9    | 1·30  | 0·30     |

*The data of nutrient level and fatty acid composition were analysed values.†Vitamin mix and mineral mix are in accordance with the American Institute of Nutrition-93 guidelines.

**Sampling**

The rats were anesthetised with halothane after the 28 d intragastric administration trial. Orbital blood was collected into coagulation promoting tubes and centrifuged at 3000 g for 10 min at 4°C. Then the serum was extracted and stored at −80°C. The rats were then killed by cervical dislocation, and liver samples were collected. About 2 cm-wide of fresh liver was collected in a CryoTube (Corning) and frozen in liquid N2 for Oil-Red-O histological assessment, another specimen of liver fixed in 10% formaldehyde for haematoxylin–eosin stain. The remainders were snap-frozen in liquid N2, and stored at −80°C for subsequent analysis of lipid metabolites, mRNA and protein expression.

**Analysis of lipid metabolites in serum**

Serum TAG, total cholesterol, NEFA and glucose were measured by using the commercial analysis kits (JiangCheng Institute of Biotechnology). The serum levels of lecithin and VLDL were determined by using ELISA kits (A&D Company Limited) according to manufacturer’s instructions.

**Hepatic histology and hepatic lipid metabolites analysis**

After being fixed in 10% formaldehyde for 24 h and dehydrated, specimens of liver were embedded in paraffin, sliced into sections of 4 μm thickness and stained with haematoxylin–eosin. For Oil-Red-O assessment, 10 μm frozen sections of liver tissue were immersed in isopropanol for 1 min and stained with Oil-Red-O for 10 min. After being washed three times with distilled water, the sections were counterstained in haematoxylin, and washed again in distilled water before microscopic analysis. The positive result of Oil-Red-O staining was bright red. Software of Image pro-plus 6.0 (Media Cybernetics) was used to estimate the positive ratio that described the percentage of the red area in each image. The levels of TAG, total cholesterol, NEFA, lecithin, VLDL and fibroblast growth factor 21 (FGF21) in liver were also measured by using the commercial analysis kits as mentioned above. Hepatic carnitine, carnitine palmityltransferase 1 (CPT1) and betaine–homocysteine methyltransferase (BHMT) levels were determined by using ELISA kits (A&D Company Limited) according to manufacturer’s instructions.

**Analysis of gene expression**

Total RNA of liver and cells were extracted by using Trizol (Invitrogen) according to the protocol provided by the manufacturer. Isolated RNA was quantified by using the NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, USA), and its integrity was confirmed by agarose gel electrophoresis. The complementary DNA (cDNA) synthesis was performed in a 20 μl reaction volume containing 2 μg total RNA, 1 μl random hexamer, 4 μl of five reaction buffer, 2 μl of 10 mmol/l deoxyribo-nucleotide triphosphate (dNTP) and 10 μl of 200 units/μl Moloney murine leukaemia virus (M-MLV). And the abundance of target gene was measured by quantitative real-time PCR analysis, using the ABI StepOne Plus™ RT-PCR system with
the SYBR® Premix Ex Taq™ (Tli RNaseH Plus) RT-PCR kit (TaKaRa), according to the manufacturer’s instructions. The primer pairs of specific genes were commercially synthesised by TaKaRa, shown in Table 2. Each sample was analysed in duplicate and the expression of the target genes were standardised by the endogenous housekeeping gene (β-actin). The reaction protocol comprised one cycle of 95°C for 2 min, thirty-five cycles of 94°C for 50 s, 60°C for 30 s and 72°C for 50 s. The gene expression was calculated by using the comparative \( \Delta\Delta CT \) method (25,26).

**Western blot analysis**

Protein of liver samples was extracted and quantified by using a Bradford protein assay kit (Bio-Rad). Briefly, liver samples were homogenised at 4°C (1 : 10, w/v) in 50 mM-Tris–HCl buffer (pH = 8·0), containing 1 mmol/l phenylmethylsulfonyl fluoride, 1 mg/ml protease inhibitor cocktail, 0·1% β-mercaptoethanol, and centrifuged at 12 000 g at 4°C for 5 min. After being heated to 95°C for 5 min, proteins were separated on SDS–PAGE gels, and then transferred onto immobilon-P polyvinylidene difluoride membranes (Millipore). After blocking with 5% non-fat milk/Tween overnight, the membranes were immuno-blotted with the antibodies specifiedanti-FGF-21 antibody (Epitomics), and a horseradish peroxidase-conjugated secondary antibody (KPL) was used in the detection of specific proteins. For examining the equal loading, β-actin antibody (Santa Cruz Biotechnology) was used as control. Finally, enhanced chemiluminescence reagent (Amersham) was used to visualise the protein bands. Band intensities were determined by using AlphaEase FC analysis software (version 4; Alpha Innotech).

**Statistical analysis**

Data analyses were performed with the SPSS 20.0 statistical software package (IBM). Statistical analysis was performed using one-way ANOVA, and was analysed further by Duncan’s multiple range test for differences among groups. Results were presented as means and standard deviations. In all analyses, the level of significant difference was set at \( P<0·05 \).

**Results**

### Assessment of body weight

Changes of body weight were shown in Table 3. The body weights of rats in high-fat group were numerically lower than those in other groups since the 14th day, but no significant difference \( (P>0·05) \) was found in body weight among experimental groups at the end of the feeding period.

### Effects of betaine on serum lipid metabolites

As shown in Table 4, compared with rats fed with the basal diet (T1), 4 weeks of high-fat diet (T3) feeding significantly elevated

---

**Table 2. Primer-pairs of target genes used for real-time PCR**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (from 5’ to 3’)</th>
<th>Reverse primer (from 5’ to 3’)</th>
<th>PCR product size (bp)</th>
<th>GenBank accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Actin</td>
<td>GGA AAT CGT GCG TGA CAT TA</td>
<td>AGG AGA GAC GCC TGG AAG GAG</td>
<td>183</td>
<td>NM_031144</td>
</tr>
<tr>
<td>BHMT</td>
<td>GGGCAGAAAGTCATGAAGCT</td>
<td>ACCAATGCACTCCCTGTTTGTA</td>
<td>108</td>
<td>NM_030850</td>
</tr>
<tr>
<td>PPARα</td>
<td>TGGCGACTACCAGTACTTAG</td>
<td>ACCAATGCATCCCCTTCCTGTTTGTA</td>
<td>167</td>
<td>M88592</td>
</tr>
<tr>
<td>FGF21</td>
<td>CGACAGAGGTATCTCTACACAGATGACG</td>
<td>GATCCATAGAGGTCCATCTCGTTGTTTT</td>
<td>206</td>
<td>NM_130752</td>
</tr>
<tr>
<td>AMPK</td>
<td>TGTGACAGCACATTACACAGGACAT</td>
<td>CCGATCTCTGTGGAGTAGACAGCAGC</td>
<td>156</td>
<td>NM_019142</td>
</tr>
<tr>
<td>CPT1</td>
<td>GCTGCGACATTACACAGGACAT</td>
<td>GTCGACCATAGAAGGCAGCAG</td>
<td>250</td>
<td>AF020776</td>
</tr>
</tbody>
</table>

BHMT, betaine–homocysteine methyltransferase; FGF21, fibroblast growth factor 21; AMPK, AMP-activated protein kinase; CPT1, carnitine palmitoyltransferase 1.

---

**Table 3. Changes of body weight during 4 weeks (g)**

<table>
<thead>
<tr>
<th></th>
<th>T1</th>
<th></th>
<th>T2</th>
<th></th>
<th>T3</th>
<th></th>
<th>T4</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>0 d</td>
<td>100-02</td>
<td>0·15</td>
<td>100-15</td>
<td>0·28</td>
<td>99-91</td>
<td>0·13</td>
<td>99-95</td>
<td>0·36</td>
</tr>
<tr>
<td>7 d</td>
<td>150-00</td>
<td>2·58</td>
<td>148-75</td>
<td>3·14</td>
<td>152-12</td>
<td>3·46</td>
<td>149-12</td>
<td>3·03</td>
</tr>
<tr>
<td>14 d</td>
<td>202-00</td>
<td>5·42</td>
<td>205-5</td>
<td>6·75</td>
<td>207-75</td>
<td>7·45</td>
<td>206-17</td>
<td>7·60</td>
</tr>
<tr>
<td>21 d</td>
<td>228-74</td>
<td>16·83</td>
<td>244-13</td>
<td>17·55</td>
<td>227-61</td>
<td>26·12</td>
<td>253-83</td>
<td>31·47</td>
</tr>
<tr>
<td>28 d</td>
<td>290-58</td>
<td>9·86</td>
<td>296-03</td>
<td>14·26</td>
<td>287-26</td>
<td>15·80</td>
<td>305-75</td>
<td>25·67</td>
</tr>
</tbody>
</table>

T1, basal diet; T2, basal diet with betaine administration; T3, high-fat diet; T4, high-fat diet with betaine administration.
Betaine increased PPARα gene expression and reversed the inhibition of carnitine palmitoyltransferase 1 gene expression induced by high-fat diet in the liver

Effects of betaine administration on the activity of CPT1 and the gene expressions of PPARα and CPT1 were shown in Fig. 4. Betaine administration in rats fed with a high-fat diet exhibited a higher activity of CPT1 (P<0.05) compared with that of high-fat diet-fed rats (Fig. 4(A)). Compared with rats fed with basal diet, high-fat diet supplementation significantly suppressed the gene expression of PPARα and CPT1 in the liver (P<0.05). In high-fat group with betaine administration, the inhibition induced by high-fat diet was reversed, oral administration of betaine significantly increasing (P<0.05) the gene expression of PPARα and CPT1 in the liver. Moreover, betaine administration rats fed with basal diet also showed elevated (P<0.05) PPARα mRNA abundance, but it had no influence on the mRNA abundance of CPT1 (Fig. 4(B) and (C)).
Betaine increased the activity, gene and protein expression of fibroblast growth factor 21, and elevated the gene expression of AMP-activated protein kinase in the liver

The changes of betaine administration on the activity, gene and protein expression of FGF21 in the liver are shown in Fig. 5(A)–(C). Compared with rats fed the basal diet (T1), the high-fat diet (T3) elevated (P<0.05) the gene expression of hepatic FGF21. Betaine administration significantly increased (P<0.05) the concentration and gene expression of hepatic FGF21 in both the basal diet (T1) and high-fat diet feeding (T3) groups. Additionally, compared with rats fed with a high-fat diet (T3), oral administration of betaine in the high-fat group (T4) significantly increased (P<0.05) the protein expression of FGF21. Regarding AMP-activated protein kinase (AMPK), compared with rats fed with the basal diet (T1), the high-fat (T3) diet increased (P<0.05) the mRNA expression of AMPK (Fig. 5(D)). Oral administration of betaine in the high-fat diet group (T4) significantly increased (P<0.05) the gene expression of AMPK compared with high-fat diet-fed rats (T3). The gene expression of AMPK in the basal diet-treated group (T1) was not affected by betaine administration.

Discussion

The present study indicated that betaine did not affect body weight in rats fed with either basal diet or high-fat diet. Variable effects of betaine on body weight were previously reported. These differences might be attributed to the diversity of animals, dietary nutrients, and trial periods, etc. TAG, cholesterol, lecithin and NEFA were the major components of plasma lipids. In this investigation, treatments of high-fat diet significantly increased the serum concentrations of TAG, lecithin and glucose, which suggested that high-fat diet might result in hyperlipidaemia. It is well-established that the intake of SFA is associated with hyperlipidaemia, diabetes and CVD. In the present study, compared with basal diet, the high-fat diet supplemented with lard oil increased the energy content as well as the SFA content in high-fat diet. Therefore, the increase in serum lipid might be associated with the differences of fatty acid composition in diets. The hyperlipidaemia caused by high-fat diet was not relieved by betaine administration in our experiment, which increased the levels of serum TAG, lecithin and glucose further compared with those of high-fat diet-fed rats. This is in line with a previous research, which suggested that betaine-supplemented pigs exhibited significantly higher plasma concentrations of TAG, phospholipids and lipoprotein cholesterol. Therefore, the effect of betaine in these parameters suggested that betaine might enhance lipid transportation accompanied with dyslipidaemia risk. The glucose increase induced by betaine was observed in basal diet-fed rats and high-fat diet-fed rats. Accordingly, it is suspected that the increase in serum glucose was due to betaine, which improved lipid and energy metabolism accompanied with decreasing uptake of serum glucose by peripheral tissues; this needs to

Table 5. Effects of betaine on hepatic lipid metabolism (Mean values and standard deviations, n = 7)

<table>
<thead>
<tr>
<th></th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>TAG (mg/g)</td>
<td>7.81</td>
<td>0.66</td>
<td>7.47</td>
<td>0.58</td>
</tr>
<tr>
<td>NEFA (µmol/g protein)</td>
<td>32.73</td>
<td>9.16</td>
<td>36.44</td>
<td>11.77</td>
</tr>
<tr>
<td>TC (mg/g)</td>
<td>2.21</td>
<td>0.17</td>
<td>2.46</td>
<td>0.47</td>
</tr>
<tr>
<td>Lecithin (mg/g)</td>
<td>1.00</td>
<td>0.05</td>
<td>1.10</td>
<td>0.05</td>
</tr>
<tr>
<td>VLDL (mg/g)</td>
<td>1.13</td>
<td>0.05</td>
<td>1.18</td>
<td>0.05</td>
</tr>
<tr>
<td>Carnitine (µmol/g)</td>
<td>2.63</td>
<td>0.25</td>
<td>2.78</td>
<td>0.14</td>
</tr>
</tbody>
</table>

T1, basal diet; T2, basal diet with betaine administration; T3, high-fat diet; T4, high-fat diet with betaine administration; TC, total cholesterol.

a,b,c Mean values with unlike superscript letters were significantly different (P<0.05).
be confirmed by further research. Our data also showed that treatment of high-fat diet significantly increased hepatic vesicular fat accumulation and Oil-Red-O-stained area, respectively. Moreover, the concentrations of TAG and NEFA in the liver were significantly increased in the group that was given the high-fat diet, indicating that high-fat diet treatment for 4 weeks led to hepatic lipid accumulation in rats. In the present study, oral administration of betaine reduced the Oil-Red-O-stained area, and normalised the concentration of hepatic TAG in rats fed with the high-fat diet, suggesting that hepatic lipid accumulation induced by high-fat diet was reversed by betaine administration.

The present study also investigated the effect of betaine on the factors playing a vital role in protecting the liver against lipid accumulation, which were altered by betaine administration. BHMT plays a critical role in the hepatic one-carbon metabolism, and converts homocysteine to methionine using betaine as a methyl donor (32). Significant increase in BHMT activity was observed in betaine administration rats given either basal diet or high-fat diet, which was accompanied with the notable increase of BHMT mRNA abundance in the high-fat group. Similarly, Kharbanda et al. (33) reported a significant increase in enzyme activity and mRNA abundance of BHMT in rats fed diets supplemented with 1% betaine for 4 weeks. Feng et al. (34) also reported that BHMT activity was significantly increased when pigs were offered 0.125% betaine. It has been well-documented that betaine supplementation enhances recycling of homocysteine for the generation of methionine and S-adenosylmethionine, and the increase of hepatic S-adenosylmethionine results in attenuation of fatty liver, by activating a cascade of events including phosphatidylcholine synthesis, formation of VLDL and transportation of hepatic lipid (35,36). Our results showed that betaine administration elevated the levels of hepatic lecithin and serum lecithin and VLDL in high-fat diet-fed rats, which suggested that betaine reversed hepatic lipid accumulation by elevated lecithin and VLDL levels via increasing the expression and activity of BHMT, thus enhancing hepatic lipid export. Besides, high-fat diet also increased the activity of BHMT in the liver. This is in agreement with Deminice et al. (36), who reported that high-fat diet treatment for 3 weeks elevated the mRNA level of BHMT. Therefore, high-fat diet might induce the enhancement of hepatic lipid export.

Owing to the specific property, CPT1 is a key rate-limiting enzyme of β-oxidation (37), and is reported to be a target of PPARα (38). PPARα, a nuclear receptor, is activated by fatty acids, and it regulates the transcription of numerous genes encoding enzymes in fatty acid oxidation and transportation (39,40). Enzyme analysis showed that betaine administration had no apparent effect on the activity of CPT1 in rats fed with basal diet. This is in agreement with Huang et al. (41), who reported that an effect of betaine on the activity of CPT1 in liver was not observed. In the present study, down-regulations of PPARα and its target (CPT1) were observed in the treatments of high-fat diet, which is consistent with the study of Deminice et al. (36), who reported that high-fat diet reduced mRNA levels for PPARα as well as its downstream targets CPT1. Oral administration of betaine in the high-fat diet rats obviously elevated the gene expression of PPARα and normalised the gene expression of CPT1 in the present study. Wang et al. (42) reported a similar result, which demonstrated that betaine supplementation (2% betaine/100 g diet) increased both PPARα and CPT1 expressions of apoE−/− mice. The gene expression of CPT1 in liver was not altered by betaine supplementation, as reported by Huang et al. (41), but, interestingly, betaine reversed the inhibition of CPT1 induced by high-fat diet in the present study. Therefore, betaine may induce the alteration of CPT1 gene expression in specific conditions, as in apoE−/− mice and high-fat feeding rats as mentioned above, which needs the support of further research.

![Fig. 3](https://www.cambridge.org/core/socialimage) (A) Effect of betaine on the activity of carnitine palmitoyltransferase 1 (CPT1) in the liver. (B) Effect of betaine on the mRNA abundance of CPT1 in the liver. Values are means (n = 7), with standard deviations represented by vertical bars. *a,b,c Mean values with unlike letters were significantly different (P < 0.05). Groups: T1, basal diet; T2, basal diet with betaine administration; T3, high-fat diet; T4, high-fat diet with betaine administration.

![Fig. 4](https://www.cambridge.org/core/socialimage) (A) Effect of betaine on the activity of carnitine palmitoyltransferase 1 (CPT1) in the liver. (B) Effect of betaine on the gene expression of PPARα in the liver. (C) Effect of betaine on the gene expression of CPT1 in the liver. Values are means (n = 7), with standard deviations represented by vertical bars. *a,b,c Mean values with unlike letters were significantly different (P < 0.05). Groups: T1, basal diet; T2, basal diet with betaine administration; T3, high-fat diet; T4, high-fat diet with betaine administration.
research. Moreover, it is well-established that AMPK indirectly increased CPT1 activity by inhibiting acetyl-CoA carboxylase activity\(^{(42,43)}\). Our data indicated that betaine significantly elevated hepatic AMPK gene expression (Fig. 5(D)), and there was a consistent response to betaine between gene expressions of AMPK and CPT1. In the present study, betaine reversed the inhibition of CPT1 gene expression induced by high-fat diet treatment, which may be due to the activation of AMPK. It can be presumed that betaine normalised fatty acid oxidation in rats fed with a high-fat diet via activating AMPK and up-regulating PPAR\(\alpha\) and CPT1 gene expression, thus preventing lipid accumulation in the liver.

FGF21, a novel metabolic regulator, is produced predominantly in the liver, and involved in the regulation of lipid metabolism, including lipolysis, fatty acid oxidation and ketogenesis\(^{(44–48)}\). In the present study, FGF21 concentration as well as its gene and protein expressions were significantly increased in betaine administration groups. FGF21 can be tightly regulated by nutrition in animal models, and previous research indicated that 2 weeks of 5% betaine feeding increased FGF21 expression 7-fold in the liver of mice\(^{(49)}\), which suggested that betaine elevated indeed the expression of FGF21. However, the relationship between BHMT and FGF21 is not clear, since the results of the present study showed that betaine administration resulted in elevation of BHMT and FGF21, whereas a previous study indicated that BHMT\(^{2/2}\) mice increased FGF21 expression\(^{(46)}\). Therefore, it can be speculated that BHMT\(^{2/2}\) mice may increase FGF21 expression via the elevation of betaine concentration instead of the direct regulation by BHMT. Chau et al.\(^{(50)}\) demonstrated that FGF21 regulates energy homeostasis through an AMPK–SIRT1 (sirtuin 1)–PGC1\(\alpha\) (peroxisome proliferator-activated receptor-\(\gamma\) co-activator 1\(\alpha\))-dependent mechanism in adipocytes. In the present study, expressions of FGF21 and AMPK were observed to be positively interrelated in response to betaine treatment. AMPK is a heterotrimeric protein that serves as a sensor of cellular energy levels, and it plays a critical role in the regulation of lipid metabolism by stimulating fatty acids oxidation, and inhibiting their synthesis\(^{(51,52)}\). Therefore, it can be speculated that betaine may activate AMPK system through up-regulating FGF21 expression, thus enhancing lipolysis in the liver. Additionally, FGF21 was reported to be regulated by PPAR\(\alpha\)\(^{(44)}\), expressions

---

**Fig. 5.** (A) Effects of betaine on the content of fibroblast growth factor 21 (FGF21) in the liver. (B) Effects of betaine on the FGF21 mRNA abundance in the liver. (C) Effects of betaine on relative protein expression of FGF21 in the liver. (D) Effects of betaine on the mRNA abundance of AMP-activated protein kinase (AMPK). Band intensities were determined by using AlphaEase FC analysis software (Alpha Innotech). Values are means (\(n = 7\)), with standard deviations represented by vertical bars. a,b,c,d Mean values with unlike letters were significantly different (\(P < 0.05\)). Groups: T1, basal diet; T2, basal diet with betaine administration; T3, high-fat diet; T4, high-fat diet with betaine administration.
of FGF21 and PPARα were observed to be positively interrelated in response to betaine treatment as well. Therefore, betaine might increase the expression of FGF21 via up-regulating PPARα in the high-fat group.

In summary, the present study indicated that betaine could alleviate hepatic lipid accumulation induced by a high-fat diet via enhancing hepatic lipid export and fatty acid oxidation. In high-fat diet-fed rats, betaine could elevate the lecithin and VLDL levels via enhancing the expression of BHMT, thus improving hepatic lipid export; meanwhile, betaine may increase the expression of CPT1 via activating PPARα, FGF21 and AMPK, thus enhancing fatty acids oxidation. Betaine could induce changes in the key factors involved in alleviating hepatic lipid accumulation, and the mechanism by which betaine regulates these key factors needs to be confirmed by further research studies.

Acknowledgements

This project was funded and supported by the National Basic Research Program of China (2012CB124705). The funding agency had no role in the design, analysis or writing of this article. The present research received no specific grant from any funding agency of commercial or not-for-profit sectors.

The authors’ contributions are as follows: J. F. and Y. W. were in charge of the whole trial; L. X., D. H., and J. W. conducted the research; L. X., D. H., Q. H., L. X., and J. W. analysed the data and wrote the manuscript.

The authors have no conflicts of interest to declare.

References


